The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review

References

• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–820.
   PubMed Web of Science ®Google Scholar
• Perry A, Stafford SL, Scheithauer BW, et al. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol. 1997;21:1455–1465.
   PubMed Web of Science ®Google Scholar
• Sahm F, Schrimpf D, Stichel D, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017;18:682–694.
   PubMed Web of Science ®Google Scholar
• Marciscano AE, Stemmer-Rachamimov AO, Niemierko A, et al. Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. J Neurosurg. 2016;124:106–114.
   PubMed Web of Science ®Google Scholar
• Adegbite AB, Khan MI, Paine KW, et al. The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg. 1983;58:51–56.
   PubMed Web of Science ®Google Scholar
• de Almeida AN, Pereira BJA, Pires Aguiar PH, et al. Clinical outcome, tumor recurrence, and causes of death: a long-term follow-up of surgically treated meningiomas. World Neurosurg. 2017;102:139–143.
   PubMed Web of Science ®Google Scholar
• McMullen KP, Stieber VW. Meningioma: current treatment options and future directions. Curr Treat Options Oncol. 2004;5:499–509.
   PubMedGoogle Scholar
• Chamberlain MC, Blumenthal DT. Intracranial meningiomas: diagnosis and treatment. Expert Rev Neurother. 2004;4:641–648.
   PubMedGoogle Scholar
• Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009;9:231–240.
   PubMed Web of Science ®Google Scholar
• Sioka C, Kyritsis AP. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol. 2009;92:1–6.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg. 1996;84:733–736.
   PubMed Web of Science ®Google Scholar
• Marosi C, Hassler M, Roessler K, et al. Meningioma. Crit Rev Oncol Hematol. 2008;67:153–171.
   PubMed Web of Science ®Google Scholar
• Wen PY, Quant E, Drappatz J, et al. Medical therapies for meningiomas. J Neurooncol. 2010;99:365–378.
   PubMed Web of Science ®Google Scholar
• Nassehi D. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema. Dan Med J. 2013;60:B4626.
   PubMed Web of Science ®Google Scholar
• Nassehi D, Dyrbye H, Andresen M, et al. Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema. APMIS. 2011;119:831–843.
   PubMed Web of Science ®Google Scholar
• Dyrbye H, Nassehi D, Sorensen LP, et al. VEGF-A mRNA measurement in meningiomas using a new simplified approach: branched DNA and chemiluminescence. Clin Neuropathol. 2016;35:13–21.
   PubMed Web of Science ®Google Scholar
• Ding YS, Wang HD, Tang K, et al. Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas. Ann Clin Lab Sci. 2008;38:344–351.
   PubMed Web of Science ®Google Scholar
• Pistolesi S, Boldrini L, Gisfredi S, et al. Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. Neuropathol Appl Neurobiol. 2004;30:118–125.
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109:187–193.
   PubMed Web of Science ®Google Scholar
• Nunes FP, Merker VL, Jennings D, et al. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PloS One. 2013;8:e59941.
   PubMed Web of Science ®Google Scholar
• Hawasli AH, Rubin JB, Tran DD, et al. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base. 2013;74:136–141.
   PubMed Web of Science ®Google Scholar
• Goutagny S, Raymond E, Sterkers O, et al. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol. 2011;22:990–991.
   PubMed Web of Science ®Google Scholar
• Alanin MC, Klausen C, Caye-Thomasen P, et al. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series. Int J Neurosci. 2016;126:1002–1006.
   PubMed Web of Science ®Google Scholar
• Grimm SA, Kumthecar P, Chamberlain MC, et al. Phase II trial of Bevacizumab in patients with surgery and radiation refractory progressive meningioma. J clin Oncol. 2015;33:2055.
   Web of Science ®Google Scholar
• Shih KC, Chowdhary S, Rosenblatt P, et al. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol. 2016;129:281–288.
   PubMed Web of Science ®Google Scholar
• Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109:63–70.
   PubMed Web of Science ®Google Scholar
• Franke AJ, Skelton WI, Woody LE, et al. Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review. Surg Neurol Int. 2018;9:133.
   PubMedGoogle Scholar
• Dasanu CA, Alvarez-Argote J, Limonadi FM, et al. Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs. Expert Opin Biol Ther. 2019;19(2):99–10.
   Web of Science ®Google Scholar
• Furuse M, Nonoguchi N, Kawabata S, et al. Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas. Radiat Oncol. 2015;10:156.
   PubMed Web of Science ®Google Scholar
• Furtner J, Schopf V, Seystahl K, et al. Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro Oncol. 2016;18:401–407.
   PubMed Web of Science ®Google Scholar
• Delishaj D, Ursino S, Pasqualetti F, et al. Bevacizumab for the treatment of radiation-induced cerebral necrosis: a systematic review of the literature. J Clin Med Res. 2017;9:273–280.
   PubMedGoogle Scholar
• Delishaj D, Ursino S, Pasqualetti F, et al. The effectiveness of bevacizumab in radionecrosis after radiosurgery of a single brain metastasis. Rare tumors. 2015;7:6018.
   PubMed Web of Science ®Google Scholar
• Tye K, Engelhard HH, Slavin KV, et al. An analysis of radiation necrosis of the central nervous system treated with bevacizumab. J Neurooncol. 2014;117:321–327.
   PubMed Web of Science ®Google Scholar